Literature DB >> 25512512

Nonredundant protective properties of FPR2/ALX in polymicrobial murine sepsis.

Thomas Gobbetti1, Sina M Coldewey2, Jianmin Chen1, Simon McArthur1, Pauline le Faouder3, Nicolas Cenac4, Roderick J Flower1, Christoph Thiemermann1, Mauro Perretti5.   

Abstract

Sepsis is characterized by overlapping phases of excessive inflammation temporally aligned with an immunosuppressed state, defining a complex clinical scenario that explains the lack of successful therapeutic options. Here we tested whether the formyl-peptide receptor 2/3 (Fpr2/3)--ortholog to human FPR2/ALX (receptor for lipoxin A4)--exerted regulatory and organ-protective functions in experimental sepsis. Coecal ligature and puncture was performed to obtain nonlethal polymicrobial sepsis, with animals receiving antibiotics and analgesics. Clinical symptoms, temperature, and heart function were monitored up to 24 h. Peritoneal lavage and plasma samples were analyzed for proinflammatory and proresolving markers of inflammation and organ dysfunction. Compared with wild-type mice, Fpr2/3(-/-) animals exhibited exacerbation of disease severity, including hypothermia and cardiac dysfunction. This scenario was paralleled by higher levels of cytokines [CXCL1 (CXC receptor ligand 1), CCL2 (CC receptor ligand 2), and TNFα] as quantified in cell-free biological fluids. Reduced monocyte recruitment in peritoneal lavages of Fpr2/3(-/-) animals was reflected by a higher granulocyte/monocyte ratio. Monitoring Fpr2/3(-/-) gene promoter activity with a GFP proxy marker revealed an over threefold increase in granulocyte and monocyte signals at 24 h post-coecal ligature and puncture, a response mediated by TNFα. Treatment with a receptor peptido-agonist conferred protection against myocardial dysfunction in wild-type, but not Fpr2/3(-/-), animals. Therefore, coordinated physio-pharmacological analyses indicate nonredundant modulatory functions for Fpr2/3 in experimental sepsis, opening new opportunities to manipulate the host response for therapeutic development.

Entities:  

Keywords:  ALX; annexin peptide; cardiac dysfunction; resolution of inflammation; therapeutic innovation

Mesh:

Substances:

Year:  2014        PMID: 25512512      PMCID: PMC4284560          DOI: 10.1073/pnas.1410938111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

1.  Impaired phagocytic mechanism in annexin 1 null macrophages.

Authors:  Simon Yona; Sigrid E M Heinsbroek; Leanne Peiser; Siamon Gordon; Mauro Perretti; Roderick J Flower
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

Review 2.  Novel therapies for sepsis: a review.

Authors:  Katherine J Deans; Michael Haley; Charles Natanson; Peter Q Eichacker; Peter C Minneci
Journal:  J Trauma       Date:  2005-04

Review 3.  Resolution of inflammation: the beginning programs the end.

Authors:  Charles N Serhan; John Savill
Journal:  Nat Immunol       Date:  2005-12       Impact factor: 25.606

4.  Annexin-1 and peptide derivatives are released by apoptotic cells and stimulate phagocytosis of apoptotic neutrophils by macrophages.

Authors:  Michael Scannell; Michelle B Flanagan; Andreas deStefani; Kieran J Wynne; Gerard Cagney; Catherine Godson; Paola Maderna
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

5.  Critical protective role for annexin 1 gene expression in the endotoxemic murine microcirculation.

Authors:  Amilcar S Damazo; Simon Yona; Fulvio D'Acquisto; Roderick J Flower; Sonia M Oliani; Mauro Perretti
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

6.  Resolvin D1 improves survival in experimental sepsis through reducing bacterial load and preventing excessive activation of inflammatory response.

Authors:  F Chen; X H Fan; Y P Wu; J L Zhu; F Wang; L L Bo; J B Li; R Bao; X M Deng
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-27       Impact factor: 3.267

7.  Annexin-1 peptide Anx-1(2-26) protects adult rat cardiac myocytes from cellular injury induced by simulated ischaemia.

Authors:  Rebecca H Ritchie; Jennifer M Gordon; Owen L Woodman; Anh H Cao; Gregory J Dusting
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

8.  Role of inducible nitric oxide synthase in the reduced responsiveness of the myocardium to catecholamines in a hyperdynamic, murine model of septic shock.

Authors:  Eberhard Barth; Peter Radermacher; Christoph Thiemermann; Sandra Weber; Michael Georgieff; Gerd Albuszies
Journal:  Crit Care Med       Date:  2006-02       Impact factor: 7.598

9.  Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality.

Authors:  Marcin F Osuchowski; Kathy Welch; Javed Siddiqui; Daniel G Remick
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

10.  Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction.

Authors:  J F Maddox; C N Serhan
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more
  48 in total

Review 1.  The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution.

Authors:  Charles N Serhan; Nan Chiang; Jesmond Dalli
Journal:  Semin Immunol       Date:  2015-04-07       Impact factor: 11.130

2.  IκB Kinase Inhibitor Attenuates Sepsis-Induced Cardiac Dysfunction in CKD.

Authors:  Jianmin Chen; Julius E Kieswich; Fausto Chiazza; Amie J Moyes; Thomas Gobbetti; Gareth S D Purvis; Daniela C F Salvatori; Nimesh S A Patel; Mauro Perretti; Adrian J Hobbs; Massimo Collino; Muhammad M Yaqoob; Christoph Thiemermann
Journal:  J Am Soc Nephrol       Date:  2016-05-06       Impact factor: 10.121

Review 3.  Programming and memory dynamics of innate leukocytes during tissue homeostasis and inflammation.

Authors:  Christina Lee; Shuo Geng; Yao Zhang; Allison Rahtes; Liwu Li
Journal:  J Leukoc Biol       Date:  2017-05-05       Impact factor: 4.962

Review 4.  Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy.

Authors:  Gabrielle Fredman; Ira Tabas
Journal:  Am J Pathol       Date:  2017-06       Impact factor: 4.307

5.  Novel Resolvin D2 Receptor Axis in Infectious Inflammation.

Authors:  Nan Chiang; Xavier de la Rosa; Stephania Libreros; Charles N Serhan
Journal:  J Immunol       Date:  2016-12-19       Impact factor: 5.422

Review 6.  Regulation of inflammation by members of the formyl-peptide receptor family.

Authors:  Keqiang Chen; Zhiyao Bao; Wanghua Gong; Peng Tang; Teizo Yoshimura; Ji Ming Wang
Journal:  J Autoimmun       Date:  2017-07-06       Impact factor: 7.094

7.  Inhibition of FPR2 impaired leukocytes recruitment and elicited non-resolving inflammation in acute heart failure.

Authors:  Vasundhara Kain; Jeevan Kumar Jadapalli; Bochra Tourki; Ganesh V Halade
Journal:  Pharmacol Res       Date:  2019-06-16       Impact factor: 7.658

8.  Endogenous Specialized Proresolving Mediator Profiles in a Novel Experimental Model of Lymphatic Obstruction and Intestinal Inflammation in African Green Monkeys.

Authors:  Felix Becker; Emily Romero; Jason Goetzmann; Dana L Hasselschwert; Beth Dray; John Vanchiere; Jane Fontenot; J Winny Yun; Paul C Norris; Luke White; Melany Musso; Charles N Serhan; J Steven Alexander; Felicity N E Gavins
Journal:  Am J Pathol       Date:  2019-10       Impact factor: 4.307

9.  Formyl-peptide receptor 2 governs leukocyte influx in local Staphylococcus aureus infections.

Authors:  Elisabeth Weiss; Dennis Hanzelmann; Beate Fehlhaber; Andreas Klos; Friederike D von Loewenich; Jan Liese; Andreas Peschel; Dorothee Kretschmer
Journal:  FASEB J       Date:  2017-08-30       Impact factor: 5.191

10.  Resolvin D1 Dampens Pulmonary Inflammation and Promotes Clearance of Nontypeable Haemophilus influenzae.

Authors:  Amanda Croasdell; Shannon H Lacy; Thomas H Thatcher; Patricia J Sime; Richard P Phipps
Journal:  J Immunol       Date:  2016-02-03       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.